About N-acetylneuraminate-9-phosphate synthase
N-acetylneuraminate-9-phosphate synthase (NANS) is a protein
from Homo sapiens identified by UniProt accession
Q9NR45, 359 residues long.
MolForge cross-references it against 0 known binders and
54 disease associations.
Target properties
| Protein name | N-acetylneuraminate-9-phosphate synthase |
| UniProt accession | Q9NR45 |
| Gene | NANS |
| Organism | Homo sapiens |
| Length | 359 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (54)
Diseases linked to this target (Open Targets).
- spondyloepimetaphyseal dysplasia, Genevieve type · score 0.77
- neurodegenerative disease · score 0.50
- pancreatic adenocarcinoma · score 0.21
- genetic disorder · score 0.19
- reticulocyte count · score 0.14
- eosinophil count · score 0.08
- primary biliary cirrhosis · score 0.08
- high density lipoprotein cholesterol measurement · score 0.08
- eosinophil percentage of leukocytes · score 0.08
- apolipoprotein A 1 measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NR45-F1 | alphafold | PREDICTED | 96.00 | — |
Amino-acid sequence (359 residues)
MPLELELCPG RWVGGQHPCF IIAEIGQNHQ GDLDVAKRMI RMAKECGADC AKFQKSELEF KFNRKALERP YTSKHSWGKT YGEHKRHLEF SHDQYRELQR YAEEVGIFFT ASGMDEMAVE FLHELNVPFF KVGSGDTNNF PYLEKTAKKG RPMVISSGMQ SMDTMKQVYQ IVKPLNPNFC FLQCTSAYPL QPEDVNLRVI SEYQKLFPDI PIGYSGHETG IAISVAAVAL GAKVLERHIT LDKTWKGSDH SASLEPGELA ELVRSVRLVE RALGSPTKQL LPCEMACNEK LGKSVVAKVK IPEGTILTMD MLTVKVGEPK GYPPEDIFNL VGKKVLVTVE EDDTIMEELV DNHGKKIKS
Explore N-acetylneuraminate-9-phosphate synthase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets